The Integrated Research Limited (ASX: IRI) share price has shot up 33% in response to its half-year profit guidance.
Integrated Research is a technology business that was set up in 1988. It monitors, troubleshoots and optimises critical technology systems. It also provides performance management and analytics for enterprise communications, collaboration, and payment systems. Some of the world’s largest banks, airlines and telecommunications businesses use Integrated Research.
Why Integrated Research Shares Rose 33%
The technology company said that whilst it is in the early stages of preparing the December 2018 half-year financial statements, it could reveal a strong result.
Revenue is expected to be between $49 million and $50.5 million, representing growth of 7% to 11% compared to the equivalent period last year. Profit after tax is expected to be between $11.1 million and $11.7 million – this will represent growth of 19% to 26%.
Looking at individual segments, licence sales are expected to grow by 17% to 23% to between $30 million and $31.5 million. The company also said the European operation saw a return to growth for the first half with a significant contribution from the Payments product line.
Today’s announcement seems to have positively surprised the market as much as the Costa Group Holdings Ltd (ASX: CGC) update disappointed investors.
Prior to today’s announcement, Integrated Research shares were down 58% in a year, so it has recovered some of that lost value. The statutory profit figures won’t be released for another month, Integrated Research thinks it will announce the result on 14 February 2019.
Unfortunately for investors who don’t own Integrated Research shares, it’s unlikely there will be much of a surprise in the upcoming audited report, so I’m not in a rush to buy shares.
The 2 rapid-growth shares in the free report below look more appealing to me.
After searching through a market with over 2,000 shares, our expert investment analyst has narrowed it down to just 2 of his favourite rapid-growth shares in a FREE report to Rask Media readers.
Over the past five years, these two shares have gone from being 'tiny caps' to being serious contenders for the ASX 200.
Idea #1 is taking on the world, starting with the huge USA market. In a just a few short years the company has snatched market share away from rivals and is on its way to being the market leader.
Idea #2 uses a 'printer and cartridge' type model to get large and established customers: a) using their healthcare industry-leading product, b) paying for it again and again and again... so it's little wonder this company is tipped to grow at a rapid pace in 2019.
Access the free report by clicking here now. Absolutely no credit card or payment details required.
Disclaimer: Any information contained in this article is limited to general financial/investment advice only. The information has not taken into account your specific needs, goals or objectives, so please consider consulting a licenced and trusted adviser before acting on the information. Please read The Rask Group’s Financial Services Guide (FSG) for more information. This article is authorised by Owen Raszkiewicz of The Rask Group, which is a corporate authorised representative No. 1264179 of Strawman Pty Ltd (ACN: 610 908 211) (AFSL: 501 223).